Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma

Published:2016-12-23 Issue:4 Volume:402 Page:637-644
ISSN:1435-2443
Container-title:Langenbeck's Archives of Surgery
language:en
Short-container-title:Langenbecks Arch Surg

Author:

Hatiboglu Gencay,Hohenfellner Markus,Arslan Aysenur,Hadaschik Boris,Teber Dogu,Radtke Jan Philipp,Hallscheidt Peter,Tolstov Yanis,Roth Wilfried,Grüllich Carsten,Huesing Johannes,Duensing Stefan,Pahernik Sascha

Funder

Bayer HealthCare

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

http://link.springer.com/article/10.1007/s00423-016-1543-8/fulltext.html

Reference26 articles.

1. Cost NG, Krabbe LM, Bagrodia A, Margulis V (2013) The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors. Curr Opin Urol 23(5):411–417. doi: 10.1097/MOU.0b013e32836320a7

2. Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, Gilligan T, Garcia J, Zhang Z, Kaouk J, Krishnamurthi V, Stephenson AJ, Fergany A, Klein EA, Uzzo RG, Chen DY, Campbell SC (2015) A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 194(2):297–303. doi: 10.1016/j.juro.2015.03.096

3. Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V (2011) The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6):912–918. doi: 10.1016/j.eururo.2011.02.032

4. Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182(3):844–853. doi: 10.1016/j.juro.2009.05.035

5. Schneider M, Schuler J, Hofflin R, Korzeniewski N, Grullich C, Roth W, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S (2014) Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. Urol Oncol 32(6):877–884. doi: 10.1016/j.urolonc.2014.03.011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative systemic treatments in renal cell carcinoma;Frontiers in Oncology;2024-05-21

2. Effects of neoadjuvant VEGF‑TKI treatment on surgery for renal cell carcinoma: A systematic review and meta‑analysis;Oncology Letters;2024-02-19

3. Genitourinary cancer neoadjuvant therapies: current and future approaches;Trends in Cancer;2023-12

4. Genomic analyses of renal cell carcinoma employing next generation sequencing;Die Onkologie;2023-06-15

5. The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer;Urologic Clinics of North America;2023-05